{"entity":{"id":"jk08","kind":"drug","name":"JK08","aka":[],"tldr":"JK08 is an experimental fusion protein or cytokine from Salubris Biotherapeutics in phase 2 trials for melanoma, colorectal cancer and non-small-cell lung cancer, aimed at CTLA-4.","summary":"JK08 is a fusion protein or cytokine developed by Salubris Biotherapeutics. Its target is CTLA-4. ClinicalTrials.gov describes the intervention as: Recombinant fusion protein consisting of two functional elements, which are a fully human monoclonal antibody, directed against CTLA-4 and a protein complex formed by the human IL-15 and the Sushi domain of human IL-15Rα. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in melanoma, colorectal cancer, non-small-cell lung cancer, bladder & urothelial cancer and head and neck squamous cell carcinoma. The largest, NCT05620134, plans to enrol 263 participants with primary completion was scheduled for 2025-10-17 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of JK08","url":"https://clinicaltrials.gov/search?intr=JK08"},{"label":"ClinicalTrials.gov NCT05620134","url":"https://clinicaltrials.gov/study/NCT05620134"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["melanoma","colorectal","nsclc","urothelial","head-and-neck","breast-hr-positive","tnbc","rcc","gastric","pancreatic","hcc","ovarian","thyroid"],"sections":[],"technologies":[],"targets":["ctla4"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05620134"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["JK08 is a recombinant fusion protein of a fully human anti-CTLA-4 antibody with a complex of human IL-15 and the sushi domain of IL-15 receptor alpha, so it blocks a checkpoint and delivers a T-cell growth signal from the same molecule (registry intervention description, NCT05620134). The IL-15 half has no target record in the corpus."],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"fusion protein or cytokine","mechanism":"Fusion protein or cytokine directed at CTLA-4, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/jk08/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"},{"id":"thyroid","kind":"cancer","name":"Thyroid cancer","route":"/cancers/thyroid/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"target":[{"id":"ctla4","kind":"target","name":"CTLA-4","route":"/targets/ctla4/"}],"trial":[{"id":"nct05620134","kind":"trial","name":"Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer","route":"/trials/nct05620134/"}],"company":[{"id":"salubris-biotherapeutics","kind":"company","name":"Salubris Biotherapeutics","route":"/companies/salubris-biotherapeutics/"}]}}